Stambler, Nancy
Progenics Pharmaceuticals (United States)
4 papers on CoChatORCID 0000-0001-9748-0722
Most cited papers
- Verified
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences
Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research
Cited by 3,307
- Verified
Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer
Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 84
- Verified
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
Petrylak, D. P., Vogelzang, N. J., Chatta, G. S., Fleming, M. T., Smith, D. C., Appleman, L. J., Hussain, A., Modiano, M., Singh, P., Tagawa, S. T., et al. (2015) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 25
- Verified
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Petrylak, D. P., Kantoff, P. W., Mega, A. E., Vogelzang, N. J., Stephenson, J., Fleming, M. T., Stambler, N., Petrini, M., Huang, K., & Israel, R. J. (2013) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 19
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free